<http://webisa.webdatacommons.org/prov/275118798>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/419277718> .
<http://webisa.webdatacommons.org/prov/108276931>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/419277718> .
<http://webisa.webdatacommons.org/419277718>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/419277718>	<http://www.w3.org/ns/prov#value>	"Europe, especially the UK and Germany, is leading the way in restricting formulary access for new drugs." .
<http://webisa.webdatacommons.org/419277718>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<biopharminternational.com> .